Interleukin-7 (IL-7), a critical cytokine in adaptive immunity, has been extensively utilized to amplify tumor-targeting T-cell functionality, with pronounced effects on CD8+ cytotoxic T lymphocyte activation and persistence [31,32,33]. Here, CD8A is linked to neoplasm.